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Abstract
Tachyzoite to bradyzoite development in Toxoplasma is marked by major changes in gene
expression resulting in a parasite that expresses a new repertoire of surface antigens hidden
inside a modified parasitophorous vacuole called the tissue cyst. The factors that control
this important life cycle transition are not well understood. Here we describe an important
transcriptional repressor mechanism controlling bradyzoite differentiation that operates in
the tachyzoite stage. The ApiAP2 factor, AP2IV-4, is a nuclear factor dynamically expressed
in late S phase through mitosis/cytokinesis of the tachyzoite cell cycle. Remarkably, deletion
of the AP2IV-4 locus resulted in the expression of a subset of bradyzoite-specific proteins in
replicating tachyzoites that included tissue cyst wall components BPK1, MCP4, CST1 and
the surface antigen SRS9. In the murine animal model, the mis-timing of bradyzoite antigens
in tachyzoites lacking AP2IV-4 caused a potent inflammatory monocyte immune response
that effectively eliminated this parasite and prevented tissue cyst formation in mouse brain
tissue. Altogether, these results indicate that suppression of bradyzoite antigens by AP2IV-
4 during acute infection is required for Toxoplasma to successfully establish a chronic infec-
tion in the immune-competent host.
Author summary
The Toxoplasma biology that underlies the establishment of a chronic infection is develop-
mental conversion of the acute tachyzoite stage into the latent bradyzoite-tissue cyst stage.
Despite the important clinical consequences of this developmental pathway, the molecular
basis of the switch mechanisms that control formation of the tissue cyst is still poorly
understood. A fundamental feature of tissue cyst formation is the expression of brady-
zoite-specific genes. Here we show the transcription factor AP2IV-4 directly silences bra-
dyzoite mRNA and protein expression in the acute tachyzoite stage demonstrating that
developmental control of tissue cyst formation is as much about when not to express bra-
dyzoite genes as it is about when to activate them. Losing the suppression of bradyzoite
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gene expression in the acute tachyzoite stage caused by deleting AP2IV-4 blocked the
establishment of chronic disease in healthy animals via increased protective immunity
suggesting a possible strategy for preventing chronic Toxoplasma infections.
Introduction
Toxoplasma gondii is an obligate intracellular parasite that exhibits a multi-host and multi-
stage developmental life cycle. Sexual stages are restricted to the gut mucosa of the feline defin-
itive host and asexual stages of the intermediate life cycle occur within any warm-blooded
host, including humans. Acute disease is generally asymptomatic in immune-competent hosts,
however, primary or recrudescent infection from latent bradyzoites in humans with AIDS,
those undergoing chemotherapy or in the unborn cause significant disease and death [1].
While the tachyzoite lytic cycle is responsible for disease pathology in human hosts, the inter-
conversion of the tachyzoite stage into the bradyzoite stage underlies chronic infection and
ensures host to host transmission [2]. Evidence indicates that the tachyzoite cell cycle is intri-
cately tied to bradyzoite differentiation with the choice to continue tachyzoite replication or
develop into the latent bradyzoite containing tissue cyst made during S phase and/or mitosis
[3, 4].
Transcriptome data demonstrates that unique changes in mRNA expression occur in the
tachyzoite cell cycle and during development [5–7]. An estimated ~5% of all transcripts are
exclusive to a single developmental stage with nearly 40% of the mRNAs in the tachyzoite divi-
sion cycle periodically expressed. How these changes are controlled is largely unknown. Early
genome mining for known gene specific transcription factors revealed two important observa-
tions. While the general transcriptional machinery is present in the genomes of Apicomplexa
species, initial studies failed to identify classic gene specific transcriptional regulators common
to higher eukaryotes. Second, an overall lack of genes encoding DNA binding proteins sug-
gested a limited arsenal from which to regulate these dynamic changes in parasite develop-
mental gene expression. In 2005, a family of DNA binding proteins (ApiAP2 factors) distantly
related to the APETALA family plant transcription factors was discovered encoded in the
genomes of Apicomplexa species [8]. In Plasmodium spp., ApiAP2 factors bind DNA with dis-
tinct sequence specificity [9, 10] via a novel domain swapping mechanism [11] and have non-
transcriptional roles in sub-telomeric chromosome biology [12]. Examples of ApiAP2 gene-
specific functions in Plasmodium falciparum are ookinete (AP2-O) and sporozoite (AP2-Sp)
ApiAP2s that serve as stage specific transcriptional activators regulating motile stages within
the mosquito definitive host [13–15]. Genetic disruption of AP2-O results in non-invasive
ookinetes [15] whereas disruption of the AP2-Sp locus yields a parasite unable to form viable
sporozoites [14]. The Toxoplasma genome encodes 67 ApiAP2 domain-containing proteins
(ToxoDB and ref. [16]), with 24 of these genes expressed cyclically during the tachyzoite divi-
sion cycle [5]. In Toxoplasma, ApiAP2s have been implicated in virulence and invasion mecha-
nisms [17], as part of chromatin remodeling complexes [18, 19] and RNA processing
machinery [20] and there is evidence for ApiAP2 factors regulating bradyzoite development.
AP2XI-4 is up-regulated during bradyzoite development and the loss of AP2XI-4 blocks the
stress-induction of some bradyzoite mRNAs, including the canonical marker, BAG1 [21]. The
novel stress-inducible transcriptional repressor AP2IX-9 acts to prevent premature commit-
ment to bradyzoite development through direct interaction with bradyzoite specific promoters
[22].
Control of chronic toxoplasmosis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007035 May 2, 2018 2 / 26
decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Here we describe the discovery of a new level of developmental control in the intermediate
life cycle that is required to establish the chronic tissue cyst stage in animals. AP2IV-4 is exclu-
sively expressed in the tachyzoite division cycle with peak expression of the encoded mRNA
and protein during early mitosis. Surprisingly, genetic knockouts of AP2IV-4 demonstrate it is
non-essential to the replicating tachyzoite but is instead critical for the suppression of brady-
zoite surface antigens and cyst wall proteins in the tachyzoite stage. Results from animal stud-
ies determined that AP2IV-4 silencing of bradyzoite gene expression is critical to enable
tachyzoites to escape an effective immune response and produce the tissue cysts required for
transmission.
Results
Many ApiAP2 factors dynamically regulated in the tachyzoite cell cycle are
nonessential for growth
Previous studies identified Toxoplasma ApiAP2 genes that are cyclically transcribed once
per tachyzoite cell cycle with the peak timing of mRNA levels distributed throughout the divi-
sion cycle [5]. The functions of periodically expressed ApiAP2 factors is largely unknown,
although it is proposed they control the remarkable "just-in-time" cell cycle transcriptome of
asexual stage Apicomplexa parasites [5, 23]. A Group-of-12 of these periodic ApiAP2 mRNAs
share overlapping cyclical profiles that reach maximum expression during the S through
mitotic phases (S/M) of the Toxoplasma tachyzoite cell cycle (Fig 1A). We made multiple
attempts to knockout each of the Group-of-12 ApiAP2 genes (Fig 1B) in a Type I RH strain
(RHΔku80Δhxgprt= RHQ strain) engineered for enhanced homologous recombination [24,
25]. The results from this series of genetic experiments were mixed; half the Group-of-12
ApiAP2 genes were successfully disrupted in the RHQ strain at relatively high prevalence
except AP2III-2 (Fig 1B), while knockouts of the other half failed repeated attempts. A recent
whole genome CRISPR screen performed in human fibroblast cells (HFF)[26] supports the
preliminary RHQ experimental sorting of Group-of-12 ApiAP2 genes into dispensable versus
required (Fig 1B, CRISPR column). Alternate developmental expression (and possible func-
tion), may help explain why half of the Group-of-12 ApiAP2s are not required for tachyzoite
growth. AP2IX-4 [27] and AP2XI-4 [21] are also expressed in bradyzoites and recent studies
indicate important roles for these factors in tissue cyst development; similarly AP2III-2,
AP2VI-1, and AP2XI-1 are expressed in tachyzoites and bradyzoites [28]. Notably, AP2VI-1
mRNA is expressed at high levels across the Toxoplasma intermediate and definitive life cycles
(the only ApiAP2 with this profile) and AP2III-2 is highly expressed in unsporulated oocysts
[28]. Three of the Group-of 12 ApiAP2 factors that were expressed in tachyzoites and not
induced by stress conditions (AP2IV-4, AP2XII-2, AP2XII-9)[28] also failed knockout
attempts in RHQ parasites and had significant negative phenotype scores in the HFF/CRISPR
study (Fig 1B).
At the mRNA level AP2IV-4 stood out as one of the most dynamic of the Group-of-12
ApiAP2s with a>10-fold change in mRNA abundance over a ~2 h period in the second half of
the tachyzoite cell cycle (Fig 1A, red curve). The failure to disrupt AP2IV-4 in RHQ parasites
indicated an important function in tachyzoite replication. To verify AP2IV-4 protein is cell
cycle regulated, we introduced three copies of the HA epitope tag in frame with the C-terminus
of the AP2IV-4 coding region by genetic knock-in, which preserved the native promoter and
genomic flanking contexts. The gene model for AP2IV-4 (http://toxodb.org/toxo/app/record/
gene/TGME49_318470) predicts a single exon structure that encodes a large protein with a
single AP2 DNA binding domain (S1A Fig, diagram), which was verified by Western analysis
of AP2IV-4HA expressing parasites (S1A Fig, gel right). As with previously tagged Toxoplasma
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ApiAP2s (e.g. ref. [5, 22]), AP2IV-4HA in the RHQ strain localized exclusively to the nucleus
(Fig 2A) and was cell cycle regulated (Fig 2A and S1B Fig) with a timing similar to its mRNA
expression profile (Fig 1A, red curve). In a randomly growing tachyzoite population, AP2IV-
4HA was detectable in 30% of vacuoles (S2A and S2B Fig) due to cell cycle periodicity. To pin-
point the exact cell cycle expression of AP2IV-4HA, co-staining with two daughter cytoskeleton
markers was utilized to define the timing of initiation, accumulation and degradation of the
AP2IV-4HA fusion protein in comparison to the earlier expressing cyclical factor AP2VI-1HA
(Fig 1A, green curve) also produced by genetic knock-in. Antibodies for the inner membrane
Fig 1. Genetic disruption of S/M regulated ApiAP2 genes. (A.) Shown are the cyclical mRNA profiles of twelve
Toxoplasma ApiAP2s (Group-of-12) that reach maximum expression in the S phase/mitotic half of the tachyzoite cell
cycle (results from our cell cycle transcriptome dataset [5]). All data points are log2 transformed and gene IDs for the
curve numbers are indicated in (B.). AP2IV-4 is one of the most dynamic cyclical ApiAP2 mRNAs (red curve,
nontransformed RMA data is minimum 6 h = 21.7 versus maximum 3 h = 433), which peaks during late S phase to
early mitosis and is down regulated by the start of G1 phase (see Fig 2). The mRNA encoding AP2VI-1 (green curve) is
similarly cell cycle regulated with peak expression slightly earlier than AP2IV-4 (B.) Multiple genetic knockout
attempts in the RHQ strain were undertaken for eleven of the Group-of-12 ApiAP2 genes (AP2XI-4 knockout results
see ref. [21]). Results: number of confirmed knockout clones (KO) versus total drug-resistant recombinants screened
by custom PCR is indicated for each Group-of-12 gene. HFF CRISPR: average phenotype score for the Group-of-12
ApiAP2 genes in a recent whole genome CRISPR analysis [26] was included as a reference. In general, negative
CRISPR phenotype scores indicate potential greater dependency for tachyzoite growth in HFF cells.
https://doi.org/10.1371/journal.ppat.1007035.g001
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complex (S1B Fig, α-TgIMC1)[29] and the apical cap (Fig 2, α-TgISP1) [30] permit the late S
phase through mitotic periods of the tachyzoite cell cycle to be resolved in time. AP2IV-4HA
first appeared in tachyzoites lacking internal daughter IMC structures as did AP2VI-1HA,
although by first AP2IV-4HA detection AP2VI-1HA had already reached maximum expression
in these parasites (S1B Fig, a vs. b images). The detection of AP2IV-4HA prior to internal
daughter structures indicates initiation of expression in late S phase just prior to the start of
mitosis and before nuclear division. The rapid accumulation of AP2IV-4HA paralleled the for-
mation of ISP1 rings of the daughter parasites (Fig 2A, a-c images) and the growth of the
Fig 2. AP2IV-4 is dynamically regulated during the tachyzoite cell cycle. AP2IV-4 and AP2VI-1 were individually
C-terminally epitope tagged with 3xHA at the endogenous loci of the RHQ strain by genetic knock-in to preserve
native promoter expression. Relative cell cycle progression for each experimental series is indicated above the images.
(A.) AP2IV-4HA expressing tachyzoites were co-stained with α-ISPI (apical cap, green) and DAPI (DNA, blue,) to
determine the exact timing of AP2IV-4HA expression (red) during the tachyzoite cell cycle. Note that intravacuole
synchronous expression of AP2IV-4HA and AP2VI-4HA is a characteristic of tachyzoite stage growth. AP2IV-4HA was
first detected (image a) prior to daughter ISP1 formation and before the nucleus flattened in late S phase. Maximum
AP2IV-4HA protein (b, c) accumulation was marked by the appearance and elongation of daughter apical structures
and U-shaped nuclear morphology. As the daughter apical cap (ISP1) matured and nuclear division was completed,
AP2IV-4HA disappeared near the end of cytokinesis (d). When all mother apical caps had been resolved and nuclear
division completed (G1 phase), AP2IV-4HA was not detectable. Scale bar = 5 μm. (B.) AP2VI-1HA parasites were also
co-stained with α-ISP1 (apical cap, green) and DAPI (DNA, blue) to pinpoint AP2VI-1HA expression (red) during the
tachyzoite cell cycle. Initiation of AP2VI-1HA expression also occurs prior to daughter apical cap formation (b) and
achieves peak stabilization as daughter apical cap is formed (c). Apical cap rings (daughter caps, arrows) signify the
degradation of AP2VI-1HA expression (d) and AP2VI-1HA is no longer detectable when the apical cap of the internal
daughters is mature (e). Nuclear morphology restricts AP2VI-1HA to S phase and early mitosis of the cell cycle, prior to
the flattened or U-shaped nucleus of mitosis. Scale bar = 5 μm.
https://doi.org/10.1371/journal.ppat.1007035.g002
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IMC1 daughter scaffold (S1B Fig, c,e images), while during these same cell cycle transitions
AP2VI-1HA declined rapidly to undetectable levels (Fig 2B, d,e images; S1B Fig, d,f images).
AP2IV-4HA was highly expressed throughout budding (distinct mitotic U-shaped nuclear mor-
phology, DAPI staining, Fig 2A) and began to disappear following nuclear division in late cyto-
kinesis (Fig 2A, images d,e) and was no longer detectable after resolution of the mother IMC,
which is consistent with the lack of AP2IV-4 mRNA expression in the G1 phase (Fig 1A).
Expression of AP2IV-4HA in tachyzoites induced to differentiate into bradyzoites by alka-
line stress followed a pattern that was consistent with known changes in replication associated
with this developmental pathway (S2 Fig)[3]. Alkaline-stress conditions caused AP2IV-4HA
parasites to loose intravacular synchronous growth and this led to a heterologous pattern of
AP2IV-4HA expression reflective of asynchronous cell cycle distributions in a single vacuole
(S2B Fig). However, co-staining alkaline-stressed populations for AP2IV-4HA and centrin,
showed that the cell cycle restriction of AP2IV-4 to the second half of the cell cycle was pre-
served in the differentiating parasites (representative image, S2C Fig). It is challenging to
resolve centrosome counts in differentiating populations due to the lack of rosetting and para-
site stacking, however, it is clear in the representative example shown that parasites lacking
AP2IV-4HA possess a single centrosome. Further, AP2IV-4HA positive parasites are wider than
their more slender "vacuolar mates", which is a recognized morphological difference between
replicating tachyzoites and dormant mature bradyzoites. Thus, during alkaline-stress induc-
tion AP2IV-4HA expression is marking those parasites that are replicating and are likely at an
earlier stage in development as growth arrest in the G1 period is the ultimate outcome of this
developmental pathway [3, 31, 32]. The expression of AP2IV-4 during early differentiation
shares similarities with another of the Group-of-12 cell cycle ApiAP2 factors that we have stud-
ied, AP2IX-4 [27].
Successful genetic knockout of AP2IV-4 indicates a nonessential role for
tachyzoite growth
The failure to disrupt the AP2IV-4 gene in the RHQ strain (Fig 1B) suggested this factor was
essential for tachyzoite growth, although other explanations such as low frequency double
crossover or growth defects preventing the recovery of AP2IV-4 knockout parasites could
explain the knockout failure. To investigate whether low frequency recombination was respon-
sible, we applied Cre-Lox methods [33] to disrupt AP2IV-4 using the rapamycin-inducible
diCRE model recently introduced into the Type I RHΔhxgprtΔku80 strain (RHCre)[33]. To
“flox” the AP2IV-4 gene in the RHCre strain, we performed serial epitope tagging by genetic
knock-in of the AP2IV-4 (3xHA tag) and TGGT1_318480 (3xmyc tag) genes (see Fig 3A dia-
gram), which are in a sequential head to tail configuration on chromosome IV. The AP2IV-
4HA fusion protein that resulted from the production of the RHCre-AP2IV-4floxed strain
(RHCre-parent in these studies) preserved the native promoter and reproduced the identical
3xHA fusion protein as was generated in the RHQ-AP2IV-4HA strain above (see Fig 2A). Gene
TGGT1_318480 is expressed at very low levels in tachyzoites or bradyzoites (<30th mRNA
percentile, ToxoDB.org) and was undetectable by both IFA and Western blot following tagging
with 3xmyc. Cre-mediated excision of the AP2IV-4 locus was induced by a 6 h incubation
with rapamycin (50nM) of RHCre-parent parasites (Fig 3A). In contrast to the failure to
knockout AP2IV-4 in the RHQ strain by conventional methods (Fig 1B), ~20% (10/51) of iso-
lated clones following rapamycin treatment of RHCre-parent parasites lacked the AP2IV-4
gene (also no longer HA+), and for two clones we verified the absence of AP2IV-4 mRNA
(S3A Fig). The isolation of viable RHCre-Δap2IV-4 transgenic parasites indicated AP2IV-4 is
not essential for tachyzoite growth.
Control of chronic toxoplasmosis
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Fig 3. Tissue cyst wall and bradyzoite surface proteins accumulate in tachyzoites lacking AP2IV-4. (A.) Schematic representation of the AP2IV-4
knockout strategy in the RHCre strain. Insertion of loxP sites surrounding the AP2IV-4 locus was accomplished by sequential epitope tagging of
TGGT1_318480 and AP2IV-4 genes utilizing the indicated tags and selectable markers. A similar strategy was also used to delete the AP2IV-4 gene in
the PruQ-parent strain (S3B Fig). Active Cre-recombinase excises the floxed AP2IV-4 gene in the dual-tagged RHCre and PruQ-strains, which are
the parents referred to in this study. Microarray analysis: selected mRNAs altered by the knockout of the AP2IV-4 gene in RHCre- and PruQ-
Δap2IV-4 parasites; average RMA values for RHCre- or PruQ-parent (carrying AP2IV-4floxed) versus Δap2IV-4 knockout transgenic strains are
shown (complete results in S1 Dataset). Note the higher baseline expression of mRNAs in the PruQ- versus the RHCre-parent strains. (B. and C.)
Average fraction of vacuoles grown under tachyzoite conditions showing DBA+ tissue cyst walls and expression of bradyzoite cyst wall proteins
Control of chronic toxoplasmosis
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Microarray analysis reveals AP2IV-4 controls bradyzoite mRNA expression
Absent a requirement for AP2IV-4 in cell division, it was not clear what role AP2IV-4 serves
in the tachyzoite. In order to build clues to understand AP2IV-4 function, duplicate total RNA
samples from the RHCre-parent and RHCre-Δap2IV-4 tachyzoites were isolated (standard
tachyzoite conditions, pH 7.0), converted to cRNA and hybridized to a custom Toxoplasma
Affymetrix GeneChip [34]. In total, 40 mRNAs were altered>2-fold in RHCre-Δap2IV-4
tachyzoites, including 26 mRNAs that were up-regulated (Fig 3A, results of selected genes;
complete results in S1 Dataset). Remarkably, the loss of AP2IV-4 caused increased expression
of mRNAs encoding known bradyzoite surface antigens (e.g. SRS9, SAG4.2) [35, 36] and cyst
wall components (e.g. BPK1, MCP4)[6, 37] in the tachyzoite. These results indicated the major
function for AP2IV-4 is to repress the transcription of key bradyzoite genes in replicating
tachyzoites. This new level of developmental control of bradyzoite gene expression in the
tachyzoite is distinct from the stress-induced AP2IX-9 mechanism we described previously
[22]. Importantly, AP2IV-4 and AP2IX-9 combined appear to transcriptionally silence 66%
(14/21, S2 Dataset) of the bradyzoite genes thought to be activated by AP2XI-4 [21], which is
also one of Group-of-12 ApiAP2s. The RHCre-Δap2IV-4 transgenic strain was complemented
with the cosmid PSBM794 [38] that carries a Toxoplasma genomic DNA fragment spanning
the AP2IV-4 gene and RNA samples from the resulting RHCre-Δap2IV-4::AP2IV-4 transgenic
strain were analyzed on the Toxoplasma GeneChip. The results from this experiment deter-
mined that reintroduction of the AP2IV-4 gene restored mRNA repression to RHCre-parent
levels for>80% of the mRNAs with the remaining mRNAs substantially reduced from the de-
repressed levels of RHCre-Δap2IV-4 tachyzoites (S1 Dataset).
To confirm the function of AP2IV-4 in a second genetic lineage, we employed the same
double-tagging strategy to "flox" the AP2IV-4 gene in the Type II Prugniaud strain (PruQ-par-
ent in this study: Pru-Δku80Δhxgprt/AP2IV-4floxed)[39] followed by knockout of the AP2IV-4
gene by transient transfection of pMIN-CRE-eGFP plasmid (S3B Fig, diagram)[40]. Two con-
firmed PruQ-Δap2IV-4 clones lacking the AP2IV-4 gene were recovered from 178 indepen-
dent clones screened (S3C Fig). The successful disruption of the AP2IV-4 locus in PruQ
confirms the dispensability of this factor for tachyzoite growth in a second genetic lineage.
BPK1, MPC4, CST1 and the bradyzoite-specific surface antigen SRS9 in the PruQ-parent, PruQ-Δap2IV-4 knockout, and PruQ-Δap2IV-4::AP2IV-4
complemented strains with representative IFA images in (C.) Statistical significance of pairwise parent versus knockout results is indicated (,
p<0.01; , p<0.001). Positive staining for each antigen and DBA+ vacuoles were quantified in triplicate by counting 100 vacuoles from randomly
selected microscopic fields. Note also the normal localization of BPK1, CST1, and MCP4 proteins in cyst walls also stained by DBA and the parasite
surface localization of SRS9. Unlike bradyzoite heterogenous expression patterns, SRS9 in PruQ-Δap2IV-4 parasites always showed uniform
intravacuolar expression consistent with the synchronous replication of tachyzoites. Scale bar = 5 μm. IFA analysis and quantification of these same
bradyzoite proteins in RHCre-Δap2IV-4 parasites is presented in supplemental (S4 Fig). (D.) To determine whether the single AP2 domain in
AP2IV-4 is capable of binding DNA, a protein binding microarray screen was completed using recombinant GST-AP2IV-4 protein (AP2 domain
only)(see Material and Methods). The consensus binding sequence from the analysis was determined to be homopolymeric poly(dC):poly(dG); (5’-
ACCCCCCT-3’/3’-TGGGGGGA-5’; enrichment score = 0.497) the representative sequence logo shown indicates position weight matrices compiled
for each base. An electrophoretic mobility shift assay was completed using 50ng of GST-AP2IV-4 protein and 20 fmol of a 59bp biotinylated DNA
probe containing one 6 and one 5 homopolymer poly(dC) stretch (36% total poly(dC) nucleotides). A slowly migrating complex was identified (lane
2, top arrow) that was specifically competed by excess unlabeled poly(dC) competitor DNA (lane 3) but not by excess scrambled DNA fragment
containing no more than three consecutive poly(dC) nucleotides (18% poly(dC) nucleotides). (E.) DDAP2IV-4 occupies the native SRS9 promoter in
parasite chromatin (see Material and Methods for ChIP-qPCR assay details). Specific DDAP2IV-4 binding was determined in eight specific regions of
the SRS9 promoter 5’ to the SRS9 coding region (-1,136 bp flanking including the SRS9 5’-UTR up to the coding ATG). The region of the SRS9
promoter between -584 bp and -192 bp (regions 5–7) showed the highest specific enrichment for DDAP2IV-4 binding. The occurrence of poly(dC) or
poly(dG) motifs (5’-3’) in the SRS9 promoter are indicated by red or yellow bars, respectively. ChIP-qPCR analysis of DDAP2IV-4 binding to the
bradyzoite-specific BAG1 promoter in tachyzoite chromatin was included here as a negative control. A previous study established that the stress-
induced ApiAP2 activator, AP2IV-3, specifically binds the BAG1 promoter [28] and is shown here only as a positive control reference. Note that the
functionally mapped BAG1 CRE [64] is indicated in the included diagram (yellow diagram). All SRS9 and BAG1 primer sets used in the ChIP-qPCR
studies are listed in S3 Dataset.
https://doi.org/10.1371/journal.ppat.1007035.g003
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Microarray analysis of PruQ-Δap2IV-4 tachyzoites identified very similar gene expression
changes to RHCre-Δap2IV-4 parasites; >90% of genes altered up or down by the loss of
AP2IV-4 in these knockout strains were shared (Fig 3A; complete lists S1 Dataset). In the
PruQ-Δap2IV-4 parasites, bradyzoite mRNA fold changes were often less than in the RHCre-
Δap2IV-4 tachyzoites due to higher starting baseline levels of mRNA expression in the PruQ-
parent strain (Fig 3A and S1 Dataset). Type II Pru strains have significant capacity to sponta-
neously form bradyzoites [28] and this raised the population baseline expression of bradyzoite
mRNAs (Fig 3A, PruQ-parent). Nonetheless, microarray studies of PruQ-Δap2IV-4 parasite
mRNA expression clearly validated the conclusion that a major function of AP2IV-4 is to
silence bradyzoite surface and cyst wall gene transcription in replicating tachyzoites.
Tachyzoites lacking AP2IV-4 misexpress cyst wall and bradyzoite surface
proteins
To verify bradyzoite-specific proteins are expressed in replicating tachyzoites lacking AP2IV-
4, we completed immunofluorescence assays (IFA) of PruQ-Δap2IV-4 (Fig 3B and 3C) as well
as RHCre-Δap2IV-4 tachyzoites (S4 Fig) using antibodies to four bradyzoite specific proteins
(α-BPK1, α-MCP4, α-CST1, α-SRS9) and also evaluated the formation of cyst walls using bio-
tin-labeled Dolichos biflorus agglutinin (DBA). Microarray probes for the recently discovered
bradyzoite cyst wall protein CST1 [41] were not included in Toxoplasma GeneChip, although
we suspected the CST1 gene could be a target of AP2IV-4 suppression in tachyzoites. This was
confirmed at the mRNA level by RT-qPCR using CST1-specific primers (see S3 Dataset for
CST1 primer designs). Staining of PruQ-Δap2IV-4 (Fig 3B and 3C) and RHCre-Δap2IV-4
tachyzoites (S4A Fig) with CST1 antibodies confirmed the mis-timing of expression of this
large cyst wall protein (>250 kDa), which was reversed by genetic rescue of these knockout
strains with a cosmid genomic clone carrying the AP2IV-4 gene (Fig 3B and S4A Fig). Similar
to CST1, the cyst wall pseudokinase BPK1 and structural protein MCP4 as well as bradyzoite
surface protein SRS9 were all increased in PruQ- and RHCre-Δap2IV-4 tachyzoites as was the
number of DBA+-vacuoles, which was again reversed by genetic complementation (Fig 3B
and 3C and S4B and S4C Fig). In comparison to alkaline-induced PruQ-parental bradyzoites,
PruQ-Δap2IV-4 tachyzoites expressed the bradyzoite mRNAs and proteins shown here within
a normal range expected of bradyzoites and the proteins were properly localized to either cyst
walls or the parasite surface (Fig 3C, see also S4B Fig). The, expression of bradyzoite-specific
genes in the Δap2IV-4 tachyzoites of either strain was the result of developmental mis-timing.
Type I RH parasites are known to be resistant to developmental induction [42], and therefore,
it was remarkable that deletion of a single ApiAP2 factor could accomplish what strong alka-
line stress fails to do in this strain. The expression of bradyzoite-specific antigens in Δap2IV-4
populations was not 100% for either strain, which likely reflects the restricted S/M cell cycle
window that AP2IV-4 operates (Figs 1 and 2). Intriguingly, we reported previously that
increased baseline bradyzoite mRNA expression occurs during the S/M periods of synchro-
nized tachyzoites [5]. This hypothesis was examined further by co-staining PruQ-Δap2IV-4
and PruQ-parent tachyzoites with α-SRS9 and α-centrin antibodies (S5A Fig). This IFA analy-
sis determined that the majority of SRS9+/PruQ-Δap2IV-4 parasites possessed duplicated cen-
trosomes (S/M phases) confirming that SRS9 misexpression was occurring primarily in the
mitotic half of the tachyzoite cell cycle. Similarly, most of the 14.3% of PruQ-parental parasites
that spontaneously expressed SRS9 also possessed duplicated centrosomes (only 3% of parental
parasites were in the G1 phase and also SRS9+). Altogether, these results are consistent with
the unique relationship between bradyzoite differentiation and tachyzoite mitosis that we dis-
covered more than a decade ago [3].
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AP2IV-4 binds DNA with sequence specificity
ApiAP2 factors have been shown to regulate gene expression through the binding of target
promoters in a sequence specific manner [9, 10, 12, 14, 15, 17, 22]. To assess DNA binding
specificity for AP2IV-4, a GST-AP2IV-4 fusion protein (AP2 domain only) was expressed,
purified and incubated on a microchip containing all possible 10-mer DNA fragments (Fig
3D, protein binding microarray results). A resulting 8-nucleotide “consensus” sequence motif
bound specifically by the GST-AP2IV-4 fusion protein contains homopolymeric poly(dC):
poly(dG) (Fig 3D, 5’-ACCCCCCT-3’/3’-TGGGGGGA-5’; enrichment score 0.497). Electro-
phoretic mobility shift assays (EMSA) using DNA probes containing poly(dC):poly(dG)
repeats were used to validate the specificity of GST-AP2IV-4 binding (Fig 3D, EMSA results)
[22]. GST-AP2IV-4 bound biotin-labeled DNA probes that contained a single instance of the
“consensus” PBM motif and a second five nucleotide poly(dC) segment (Fig 3D, lane 2), and
was successfully competed using 300x excess unlabeled poly(dC) competitor DNA (Fig 3D,
lane 3), but not with unlabeled DNA probes that contained no poly(dC) stretch greater than
three nucleotides (Fig 3D, lane 4). In a larger protein binding screen of 46 Toxoplasma AP2
domains, two other ApiAP2 factors, AP2VIIa-5 and AP2XII-4, were determined to also specif-
ically bind homopolymeric poly(dC):poly(dG) DNA (Kim et al, in preparation). In addition, a
recent analysis of nucleosome-free regions for enriched DNA motifs discovered poly(dC):poly
(dG) repeats were preferentially found upstream of cell cycle and bradyzoite genes, such as
SRS9 (Wang et al, in preparation).
The presence of poly(dC):poly(dG) repeats in the SRS9 promoter (Fig 3E, blue legend) sug-
gested AP2IV-4 might directly bind this promoter. To examine this question, we utilized the
FKBP (DD)/Shield 1 conditional expression model [43] in order to improve the signal strength
for AP2IV-4 expression, which has been very successful for studying ApiAP2 factors in P. fal-
ciparum and Toxoplasma [13, 22, 44]. The FKBP peptide combined with three copies of the
HA epitope tag was fused to the N-terminus of the AP2IV-4 coding region (DDAP2IV-4) by
genetic knock-in methods. The addition of Shield 1 (100nM) to RHQ-DDAP2IV-4 transgenic
parasites successfully increased nuclear levels of DDAP2IV-4, but did not disrupt the normal
periodic cell cycle expression of this protein. Thus, there are likely significant post-transcrip-
tional mechanisms regulating AP2IV-4 expression in tachyzoites as we also previously docu-
mented for AP2IX-9 expression [22]. Utilizing lysates prepared from RHQ-DDAP2IV-4
tachyzoites incubated with Shield 1, we performed chromatin immunoprecipitation followed
by quantitative PCR of eight regions covering ~1,200bp of the SRS9 promoter and 5’-UTR (Fig
3E). The results from this experiment showed that binding of DDAP2IV-4 to the SRS9 pro-
moter in parasite chromatin was enriched in regions 5–7 that includes a poly(dG) motif
(region 7, yellow bar) ~230bp upstream of the SRS9 ATG (Fig 3E). To control for non-specific
binding, we analyzed DDAP2IV-4 binding to the chromosome region (-950 bp) 5’-flanking of
the BAG1 bradyzoite gene. In contrast to stress-induced AP2IV-3, which we have recently
reported activates BAG1 [28], AP2IV-4 does not regulate BAG1 (S1 Dataset). No enrichment
of DDAP2IV-4 binding was detected to the six regions tested within the BAG1 promoter (Fig
3E), whereas DDAP2IV-3 binding to this promoter is significantly enriched [28] (Fig 3E, refer-
ence line graph).
The loss of AP2IV-4 prevents tissue cyst formation in vivo
Our results indicated that PruQ-Δap2IV-4 parasites are tachyzoites expressing a few genes that
are normally induced to high levels during bradyzoite development. Unlike bradyzoites (S2B
and S2C Fig), RHCre- and PruQ-Δap2IV-4 tachyzoites replicated synchronously within a
shared vacuole, which is a growth behavior observed for all native tachyzoite strains. PruQ-
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Δap2IV-4 parasites also retained normal SAG1 surface antigen expression even as they also
expressed bradyzoite-specific surface antigen, SRS9 (S5B Fig). Finally, whole-cell mRNA anal-
ysis of PruQ-parent and PruQ-Δap2IV-4 tachyzoites revealed nearly identical transcriptomes
(S5C Fig), whereas, the transcriptomes of native Type II tachyzoites and bradyzoites have
numerous differences and lower quantitative similarity (S5C Fig).
RHCre-Δap2IV-4 tachyzoites are a Type I strain and consistent with the limited number of
genes regulated by AP2IV-4 the knockout of this gene did not disrupt the lethality of the Type
I genetic background. Inoculation (i.p) of BALB/c mice with 500 RHCre-Δap2IV-4 (or RHCre-
parent) parasites was fully lethal, while infections with a very high dose (1x107) of PruQ-
Δap2IV-4 parasites was not (Fig 4A). These data are consistent with the known difference in the
virulence of Type I versus II strains, and while the PruQ-parent strain showed slightly higher
virulence (LD100>106) this difference was minor compared to the acute virulence of RHCre
strains lacking AP2IV-4. By contrast, the loss of AP2IV-4 had a dramatic effect on PruQ-strain
chronic infections in mice. Shifting PruQ-Δap2IV-4 parasites into alkaline media (pH8.2) effec-
tively slowed growth and induced high levels of DBA+ tissue cysts (Fig 4B, in vitro = 93.1%)
demonstrating PruQ-Δap2IV-4 parasites were capable of forming cysts in vitro. However,
PruQ-Δap2IV-4 infections of BALB/c mice failed to produce tissue cysts in brain tissue (Fig 4B).
The lack of tissue cyst formation was correlated with a lower parasite burden measured in
BALB/c mice at 6 days post-inoculation (Fig 4C), although lower parasite burden was not due
to an inability of PruQ-Δap2IV-4 parasites to replicate in vivo. Mice infected intraperitoneally
with PruQ-Δap2IV-4 display no reduction in the frequency of infection or growth as compared
to the PruQ-parent or the complemented strain at day one post infection (Fig 4D and S6A Fig),
which is in agreement with the lack of any growth difference of these strains in HFF cell culture.
This indicates that PruQ-Δap2IV-4 parasites efficiently invade host cells and replicate produc-
tively early in the infection, but as the infection progresses the parasites that lack AP2IV-4 are
more effectively eliminated by the immune response of BALB/c mice.
Mis-timing of bradyzoite protein expression in tachyzoites recruits an
effective host immune response
The development of bradyzoites and cysts in vivo is, at least partly, dependent upon immune
factors. This is illustrated in immune deficient animals where bradyzoites fail to develop and
mice succumb due to uncontrolled tachyzoite replication. The protective immune response
during acute infection is dominated by the recruitment of inflammatory monocytes and T cell
production of IFN-γ [45]. During chronic infection, IFN- γ is required to prevent parasite
recrudescence. Yet, the host immune response is unable to clear the bradyzoite and cysts per-
sist for long periods in host tissues. The pay off between protection and the development of
chronic infection is poorly understood. At day 6 post Toxoplasma infection neutrophils and
inflammatory monocytes, distinguished by their expression of Ly6 surface antigens and dis-
tinct morphologies (Fig 5A and 5B), are present at the site of infection. Although neutrophils
are important sources of IL-12, inflammatory monocytes are the key effector cell in controlling
parasite replication [46]. Analysis of the proportion of these populations following infection of
parasites with an intact or disrupted AP2IV-4 gene revealed striking differences. Consistent
with the response to a high inoculum of parasites [46], infection with the PruQ-parent induced
the influx of neutrophils, outweighing inflammatory monocytes nearly 3-fold (Fig 5A, 5B and
5D). By contrast, PruQ-Δap2IV-4 infections at day 6 post-infection led to a significant increase
in the proportion of inflammatory monocytes (Fig 5A) that was not observed early in the
infection (S6A Fig). This was confirmed by cytospin, where large numbers of polymorphonu-
clear neutrophils can be seen in the peritoneal exudate wash of mice infected with PruQ-
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Fig 4. Loss of AP2IV-4 affects the establishment of chronic disease in mice. (A.) Inoculation (i.p.) of BALB/c mice with
AP2IV-4 knockout strains; PruQ-Δap2IV-4 or RHCre-Δap2IV-4 and parental PruQ- or RHCre-strains recapitulates the
acute virulence of Type I versus relative avirulence of the Type II genetic background. RHCre-strain infection dose = 500
parasites, PruQ-strain infection dose = 1x107 parasites. Note that all mice survive an infection with 1x106 or lower dose of
PruQ-parent parasites for at least 30 days (see B.), while mice did not survive the 1x107 dose indicating PruQ-Δap2IV-4,
parasites are slightly more avirulent than the matched parent strain. (B.) PruQ-Δap2IV-4 parasites were induced by
alkaline-stress (72 h, pH 8.2 media) to form tissue cysts (DBA+) at high levels in HFF cells, whereas, these parasites were
unable to form tissue cysts in brain tissue of BALB/c mice compared to the PruQ-parent strain. Tissue cysts numbers in
mice were determined at 30 day post-infection. (C.) At six-days post infection, total DNA was extracted from peripheral
tissues and parasite burden for PruQ-parent, PruQ-Δap2IV-4, and PruQ-Δap2IV-4:AP2IV-4 strain-infections determined
following amplification of the B1 gene compared against a standard curve. Statistical significance (, p<0.05) is indicated.
(D.) BALB/c mice were inoculated intraperitoneally with 1x107 parasites of either PruQ-parent, PruQ-Δap2IV-4, or PruQ-
Δap2IV-4:AP2IV-4 strains. At day one post-infection peritoneal cells were harvested and spun onto cytospin slides. Slides
were stained using HEMA3 staining kit and examined under a light microscope. The infection frequency and parasite
vacuole size was determined in triplicate. Note that there is no significant difference in the infection frequency for any of
these strains at the early timepoint post-infection (see also S6A Fig).
https://doi.org/10.1371/journal.ppat.1007035.g004
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parental parasites and foamy monocytes observed with PruQ-Δap2IV-4 parasite infection (Fig
5B). Further, the absolute numbers of inflammatory monocytes recruited to the site of infec-
tion is greater in the absence of AP2IV-4 with a corresponding decrease in the recruitment of
neutrophils (Fig 5C and 5D). Although PruQ-Δap2IV-4 parasites can be found replicating in
peritoneal exudate cells, cytospin counts suggest that overall, the proportion of inflammatory
monocytes infected with this strain is highly reduced at day 6 post-infection (S6B Fig). Genetic
complementation of the PruQ-Δap2IV-4 parasites restored the innate immune response to
that of mice infected with the PruQ-parent (Fig 5 and S6B Fig). Together, these data indicate
that in the absence of AP2IV-4 silencing of bradyzoite gene expression in the tachyzoite stage,
there is an amplification of the protective innate immune response driven by inflammatory
monocytes.
Discussion
The life cycle of Toxoplasma is heteroxenous with a sexual definitive cycle in the felid host
and a second intermediate life cycle in any endothermic animal including humans. The
steps of the intermediate life cycle leading to tissues cysts in murine brain tissue illustrate this
Fig 5. Infection with PruQ-Δap2IV-4 tachyzoites preferentially recruits inflammatory monocytes. (A.) Peritoneal exudate cells
were harvested at day six post-infection from mice inoculated with either PruQ-parent, PruQ-Δap2IV-4, or PruQ-Δap2IV-4:AP2IV-
4 strains and subjected to immunostaining for flow cytometry. Cells were stained for extracellular antigens, and gated on CD45
+ cells for analysis. Inflammatory monocytes (Ly6Chi, Ly6Gneg) and neutrophils (Ly6Cint Ly6Ghi) were determined and averaged
(B.) Representative cytospin images are provided immediately below the matching FACS plots. (C.) Total cell infiltration into the
peritoneum of infected mice. Cell counts were quantified based on volume recovered from the peritoneal wash. (D.) Absolute cell
quantification of inflammatory monocytes and neutrophils. Data are representative of a minimum of 4 individual experiments and 5
mice per group. Statistical significance (, p<0.05; , p<0.01) is indicated.
https://doi.org/10.1371/journal.ppat.1007035.g005
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developmental process [4]. Bradyzoite/sporozoite oral infection leads to population wide
development of the tachyzoite stage [47, 48] that is followed by systemic spread of tachyzoites.
In particular, spread into the vasculature resulting in the infection of endothelial cells of brain
capillaries is a critical route for tachyzoites to cross the BBB into the brain [49]. Through
poorly understood mechanisms, the tachyzoites slow growth [4] and alter their transcriptome
to form dormant bradyzoite-tissue cysts in neurons [50] setting the stage for transmission to
the next host animal. Thus, there are two competing demands of the Toxoplasma intermediate
life cycle; expand tachyzoite numbers to ensure systemic spread within a host [49] and produce
the dormant bradyzoite-tissue cyst required for passing the infection onto a new host [4]. How
Toxoplasma mechanistically balances these competing demands is not understood. However,
clues are emerging from our studies of ApiAP2 factors (see Fig 6 model). Early bradyzoite
development is associated with the induction of six Toxoplasma ApiAP2 genes (AP2Ib-1,
AP2IV-3, AP2VI-3, AP2VIIa-1, AP2VIII-4, AP2IX-9) that are not expressed in the tachyzoite
[22, 28]. Remarkably, these factors do not operate in the same direction. AP2IX-9, is a stress-
inducible repressor of bradyzoite gene expression [22], while AP2IV-3 is a stress-induced tran-
scriptional activator (and likely AP2Ib-1) regulating many of the same bradyzoite genes as
AP2IX-9 [28]. The studies here add unexpected new complexity to bradyzoite developmental
gene expression. AP2IV-4 was the first transcription factor expressed in replicating tachyzoites
whose major function is the regulation of tissue cyst formation. Thus, our studies have uncov-
ered a complex ApiAP2 transcriptional network of repressors and activators competing at the
interface of tachyzoite replication and early switching to regulate tissue cyst formation (see Fig
6 model). Notably, we have not yet identified an ApiAP2 that exclusively operates late in bra-
dyzoite development. For the ApiAP2 gene family, the most distinguishing feature of mature
bradyzoites is the down regulation of many ApiAP2 factors [28].
Does the lack of ApiAP2 factors specific for mature bradyzoites mean that once initiated
bradyzoite development in vivo progresses to maturity? Answering this question will be chal-
lenging given the asynchrony of bradyzoite development. However, a recent analysis of tissue
cyst biology provides two important insights; tissue cyst size in the infected murine brain is
related to tachyzoite vacuole size at the time of switching and average cyst numbers in tissues
like murine brain become stable after an early period [28]. Add to this the observation that tis-
sue cyst recrudesence is rare in the brain of immune-competent animals [51], returns the
Fig 6. ApiAP2 transcriptional network controlling bradyzoite development. Transcriptional activators AP2XI-4
[21] and AP2IV-3 [28] co-regulate BAG1 and LDH2 genes and independently regulate other bradyzoite genes
(representative genes shown, see S2 Dataset for complete gene lists). Similarly, transcriptional repressors AP2IV-4 and
AP2IX-9 [22] regulate common (B-NTPase, MCP4, BPK1) and independent sets of bradyzoite genes. Note, AP2XI-4
and AP2IV-4 are Group-of-12 cell cycle ApiAP2s of tachyzoites (Fig 1), while AP2IV-3 and AP2IX-9 are stress-
inducible factors not expressed in replicating tachyzoites [22, 28].
https://doi.org/10.1371/journal.ppat.1007035.g006
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discussion to the critical importance of the tachyzoite stage for fulfilling the biotic demands of
the intermediate life cycle. The discovery of AP2IV-4 highlights the concept that specific life
cycle decisions begin upstream in the developmental pathway and provides insight into the
mechanisms that link the tachyzoite cell cycle to bradyzoite development. Together, the cell
cycle AP2IV-4 and the stress-inducible AP2IX-9, comprise two independent levels of tran-
scriptional regulation preventing bradyzoite development in Toxoplasma. This is convincing
support for the hypothesis that tachyzoite growth is the primary driver of parasite biomass and
through dissemination the tachyzoite finds suitable host cell environments for which to
develop ultimately end-stage bradyzoites [4, 22]. In addition, the overlap of gene regulatory
targets between AP2IV-4 and AP2IX-9 (S2 Dataset) indicate there is some redundancy gov-
erning the induction of the bradyzoite developmental pathway indicating the importance of
preventing premature commitment to the bradyzoite stage that leads to dormancy [22]. The
earliest clues to unfolding bradyzoite development in Toxoplasma revolves around the central
role asexual stage replication plays in the transition to growth-arrested end-stages [3, 31, 52].
DNA replication in the tachyzoite is required for bradyzoite development [52] and the tachy-
zoite is “poised” to enter the bradyzoite developmental pathway during each round of replica-
tion [3]. The sub-transcriptome of the tachyzoite S and mitotic phases is enriched in basal
bradyzoite transcripts [5] and developing populations have more 2N parasites [3], which is a
cell cycle timing that corresponds with peak AP2IV-4 expression. This places AP2IV-4 per-
fectly within the tachyzoite cell cycle to regulate these critical developmental processes.
Repressing tissue cyst wall formation in the tachyzoite could provide the parasite with flexibil-
ity to maintain a replicative stage or quickly interpret “development” signals in the animal
resulting in induction of bradyzoite differentiation when the parasite encounters the immune
system and/or a tissue that favors tissue cyst longevity. In addition to controlling when and
where tissue cyst formation occurs, repressors like AP2IV-4 may need to be re-expressed for
pre-bradyzoites or bradyzoites to recrudesce. Consistent with this idea, our previous studies
demonstrated bradyzoites from murine brain cysts re-express tachyzoite antigens prior to
their first division in HFF cells and most bradyzoites that failed to re-express them did not
divide [3].
These studies also demonstrate that deletion of a single ApiAP2 factor in Toxoplasma can
significantly alter the course of the host immune response. Thus, host influences on ApiAP2
evolution has likely led to mechanisms that suppress bradyzoite antigens during acute infec-
tion, which we show here is required to establish a chronic infection in the murine brain.
There are implications from this discovery for future vaccine development that might block
tissue cyst formation in food animals, and thereby eliminate this source of human infections,
which is an unmet therapeutic challenge. Our results point to inflammatory monocytes as a
major component of the immune response contributing to protective immunity in the absence
of AP2IV-4 (Fig 5) [45, 53]. A rapid response to the signature of a fast replicating lytic parasite
is appropriate but there would be little evolutionary drive to respond equivalently to a slow
replicating cyst form. Thus, changing the signatures of the parasite as we have done here with
the deletion of AP2IV-4 have dramatically altered the early immune response, with bradyzoite
antigens now being seen in the context of significant cell lysis. Increased inflammatory mono-
cyte recruitment may point to a change in the ability of the parasite to be seen by the innate
immune response. This could be either increased TLR recognition of bradyzoite antigens or a
failure to inhibit signaling pathways by the tachyzoite. Perhaps predictably in the presence of
enhanced monocyte recruitment, the T cell response is also superior, and the adaptive immune
response to these parasites will be of significant interest in future studies. Alternatively, the
mis-timing of bradyzoite antigen expression in the replicating and systemic tachyzoites lacking
AP2IV-4 may increase the overall function of the immune response by either targeting it more
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rapidly to the bradyzoite or act as an adjuvant to the overall anti-parasite response. Further
studies will be needed to fully understand the molecular mechanism(s) responsible for the
shift to a more protective immune response. It is worth noting that the functions now emerg-
ing for AP2IV-4 in controlling in vivo persistence were not uncovered by cell culture models.
Achieving bradyzoite switching in vitro in the mid-90’s was a major breakthrough, and much
has and will be learned using these models [54, 55]. However, the complexity of parasite
encounters with host cells and tissues in animals cannot be replicated by these models. Distinct
tissue tropisms observed for tissue cyst formation in animals infected with Toxoplasma [47,
56–58] suggest the parasite senses different host cell environments and relays this information
to the mechanisms controlling developmental switching [4]. We know little about the molecu-
lar basis for Toxoplasma host tissue tropisms, however, it is likely that the network of ApiAP2
repressors and activators we have discovered will have critical roles in these host-parasite
interactions.
Materials and methods
A summary analysis of the AP2IV-4 microarray data can be found in S1 Dataset. For a com-
parative analysis of genes regulated by AP2IV-3, AP2XI-4, AP2IV-4 and AP2IX-9, please see
S2 Dataset. All new gene expression data sets produced in this study have been uploaded to the
Gene Expression Omnibus (GSE93531). All transgenic strains and oligonucleotides used in
this study are found in S3 Dataset
Cell culture, genetic manipulation and conditional genome engineering
Toxoplasma tachyzoites were serially passaged in vitro using confluent tissue culture flasks
(T25cm2 and T175cm2) containing human foreskin fibroblasts (HFF cells; obtained from
ATCC, Manassas, VA).
Conventional ApiAP2 knockouts. To create ApiAP2 gene replacement plasmids for
Group-of-12 factors (Fig 1), the 5’ UTR and 3’UTR regions (>500bp each flank) were PCR
amplified from RH genomic DNA and cloned via the BP reaction into pDONRP4-P1R or
pDONRP2R-P3, respectively. The pDONRP1-P2 plasmid containing the HXGPRT selectable
marker is described [59]. Finally, the three entry plasmids (5’ApiAP2 UTR:HXGPRT:3’A-
piAP2) were combined in the LR reaction with pDESTP4-P3 to create the expression plasmid
pDEST"ApiAP2" HXGPRT KO. All BP and LR reactions were done according to manufactur-
er’s protocol (Thermo Fisher); 25μg of pDEST"ApiAP2" HXGPRT KO plasmid was transfected
into 2.5x107 RHQ tachyzoites then parasites were selected in media supplemented with xan-
thine (40μg/ml) and mycophenolic acid (50μg/ml). When drug resistant parasites were
observed, clones were isolated by limiting dilution.
Introduction of loxP recognition sites. loxP recognition sites were introduced by inverse
PCR amplification of the pLIC-3xHA/DHFR and pLIC-3xmyc/HXGPRT plasmids, followed
by ApaI digestion of the linear PCR product and T4 DNA ligation to re-circularize the plas-
mid. This resulted in the introduction of a loxP site downstream of the indicated T. gondii
selectable marker (ex. Fig 3A), creating the plasmids pLIC3xmyc/HXGPRT/loxP and pLIC-
3xHA/DHFR/loxP. Toxoplasma gene TGGT1_318480 was fused with a triple repeat of the
myc3 epitope in RHCre or PruQ by homologous recombination using the pLIC3xmyc/
HXGPRT/loxP plasmid. Likewise, AP2IV-4 (TGGT1_318470) was fused with a triple HA epi-
tope in clonal isolates of RHCre-318480myc or PruQ-318480myc by homologous recombination
with the pLIC-3xHA/DHFR/loxP plasmid, thereby “floxing” the AP2IV-4 genomic locus.
Rearrangement of the genetic locus of interest was verified by nested PCR for all clones iso-
lated. Please see S3 Dataset for strain details and oligonucleotide sequences.
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CRE-recombinase expression. Expression of CRE-recombinase strain was induced in
RHCre-AP2IV-4floxed parasites as previously described [33]. To initiate CRE mediated excision
of AP2IV-4, RHCre-AP2IV-4floxed parasites were seeded at a 5:1 MOI in HFF monolayers,
allowed to invade for 2 h, washed 3x with Hanks balanced salt solution (Corning) to remove
all free floating parasites and followed by 6 h treatment with 50nM rapamycin. The monolay-
ers were scraped, twice passaged through a 25ga needle, filtered to remove host debris and
immediately cloned by limiting dilution to reduce competition from the background of "wild
type" AP2IV-4 parasites. For PruQ-AP2IV-4floxed, 5x107 parasites were transfected with 25μg
of pMIN-CRE-eGFP plasmid [40], allowed to recover for 24 h, scraped, force lysed by passage
through a 25ga needle, filtered and immediately cloned by limiting dilution.
Cosmid complementation. Cosmid isolates that span the AP2IV-4 locus were identified
with the gBrowse function at www.ToxoDB.org. PSBM794 was selected and 10μg of cosmid
DNA was transfected into 1x107 RHCre-Δap2IV-4 or PruQ-Δap2IV-4 parasites and a stable
population selected using two rounds of phleomycin (5mg/ml for 10 h, followed by sustained
5μg/ml) selection.
Conditional expression of AP2IV-4. The AP2IV-4 (TGGT1_318470) coding sequence
was PCR amplified from RH genomic DNA with oligonucleotides that included in-frame
MfeI/EcoRV sites, which were used to clone the PCR fragment into the pCTDDHA3x plasmid
(Dr. Boris Striepen, University of Georgia). The resulting plasmid, pCTDDHA3x-AP2IV-4,
contains an N-terminal fusion of the FKBP peptide (11.2 kDa) and a triple repeat of the HA
epitope (4.4 kDa) fused in-frame with AP2IV-4 (DDAP2IV-4) that allows for ectopic condi-
tional expression of the fusion protein using the small molecule Shield 1 [22]. The plasmid was
transfected into the RHQ strain and transgenic parasites selected using chloramphenicol
(20 μM) with individual clones isolated by limiting dilution.
Endogenous epitope fusions with 3xHA. Toxoplasma genes AP2IV-4 (TGGT1_318470)
and AP2VI-1 (TGGT1_240460) were tagged at the genomic locus with a triple copy of HA in
RHQ by homologous recombination using the pLIC-3xHA/DHFR plasmid as previously
described [25].
Immunofluorescence assays and Western analysis
Parasites were grown in confluent HFF cells and prepared for immunofluorescence as previ-
ously described [60]. Primary antibodies were used at the following concentrations: HA (rat
mAb 3F10, 1:500, Roche); ISP1 (mouse mAb clone 7E8, 1:2000, Dr. Peter Bradley, University of
California, Los Angeles); IMC1 (mouse mAb, 1:1000, Dr. Gary Ward, University of Vermont);
biotin-labeled Dolichos biflorus agglutinin (DBA) (Vector labs, CA,1:3000); BPK1, MCP4 and
SAG1 (mouse polyclonal antibodies = pAbs, 1:1000, Dr. John Boothroyd, Stanford University,);
CST1 (mouse pAb, Salmon E, 1:2000, Dr. Louis Weiss, Albert Einstein College of Medicine);
SRS9 (rabbit pAb, 1:1000, Dr. Laura Knoll, University of Wisconsin). Secondary antibodies by
Alexa or streptavidin conjugated secondary antibodies were used at a 1:1000 dilution. All
images were collected with a Zeiss Axiovert microscope equipped with 100x objective. Statistical
significance was calculated using the one-tailed t-test, p values as indicated.
Protein from 25x106 parasites were isolated, purified and whole parasite lysates collected as
previously described [60] and subjected to electrophoresis on a SDS-PAGE gel. After transfer
to nitrocellulose, the blots were probed with primary antibodies for CST1 (mouse pAb, Salmon
E, 1:2000, Dr. Louis Weiss, Albert Einstein College of Medicine) and the loading control
TgNF3 (mouse pAb, 1:1000, Dr. Stan Tomavo, Pasteur Institute, Lille)[61]. Detection of the
proteins was completed using HRP conjugated antibodies (Jackson ImmunoResearch) fol-
lowed by chemiluminescence reaction for visualization.
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RNA microarray
Two independent biological replicates of total RNA were isolated from five RHCre transgenic
strains (S3 Dataset): RHCre-AP2IV-4floxed clone ID6 (RHCre-parent), RHCre-Δap2IV-4
clones 27 and 30, and cosmid complemented populations (PSBM794; RHCre-Δap2IV-4::
AP2IV-4) of each knockout. Likewise, two biological replicates were isolated from the follow-
ing PruQ strain transgenics (3 total strains): PruQ-AP2IV-4floxed clone C3 (PruQ-parent),
PruQ-Δap2IV-4 clones 10 and 34. RNA quality for all strains was evaluated using the Agilent
Bioanalyzer 2100 (Santa Clara, CA) and 500ng of total RNA was prepared for hybridization on
the ToxoGeneChip as described [5]. The resulting data was analyzed using GeneSpring GX
software (v11.5, Agilent) and all microarray data made available in the Gene Expression Omni-
bus (GSE93531).
Protein expression and electrophoretic mobility shift assay (EMSA)
The AP2 domain (amino acids 782–854) of AP2IV-4 was cloned into pGEX4T3 and expressed
as a GST-fusion protein. Following affinity purification on a glutathione column, purified
GST-AP2IV-4 protein was subjected to protein binding microarrays as previously described
[9, 22]. Complementary oligonucleotides were annealed to create 5’-biotinylated DNA probes
of 59bp (WT) and 60bp (scrambled). All binding reactions contained 20fmol DNA probe and
50ng of GST-AP2IV-4 protein. Non-biotinylated “cold” competitor probe was added at 300x
concentration. GST-AP2IV-4-DNA complexes were resolved on a 6% polyacrylamide PAGE
gel, transferred to a nylon membrane and interactions visualized using the LightShift Chemilu-
minescent EMSA kit as described by the manufacturer (Thermo Fisher, Waltham, MA). Oli-
gonucleotide sequences used for GST-AP2IV-4 expression and DNA probes can be found in
S3 Dataset.
Chromatin immunoprecipitation and qPCR
Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) was performed
as previously published (supplement of ref. [22]). In brief, RH-DDAP2IV-4 and RHΔhxgprt
(negative control) parasites were inoculated at 3:1 MOI in T175 cm2 flasks, allowed to invade
for 1 h, rinsed three times with Hanks balanced salt solution (Gibco) to remove free floating
parasites and fresh media containing 100nM Shield 1 was added. Parasite cultures were
allowed to grow 36 h prior to intracellular crosslinking with formaldehyde and isolation of
nuclear fraction. Nuclear material was subjected to sonication to shear DNA into 200-1000bp
fragments and soluble fraction incubated with α-HA antibody (5μg, ab9110, rabbit, Abcam).
Protein-DNA complexes were isolated using protein-G coupled magnetic beads (Dynabeads,
Invitrogen) and DNA isolated by treatment with 1% SDS followed by phenol-chloroform
extraction and ethanol precipitation. Whole genome amplification (Sigma-Aldrich) was per-
formed on ChIP-DNA and purified by Qiagen Mini-Elute PCR kit. qPCR was performed
using 20ng/rxn of specific (DDAP2IV-4) chromatin and non-specific chromatin (RHΔhxgprt)
using Fast SYBR green master mix on an ABI7900 according to manufacturer’s protocols. Rel-
ative enrichment was calculated with the equation: 2^-(ΔCt target-ΔCt non-target) where the change
in Ct value of specific versus nonspecific chromatin at the SRS9 and BAG1 promoters was cal-
culated. All ChIP-qPCR oligonucleotides used can be found in S3 Dataset.
Animals and infections
Mice were purchased from Jackson or Harlan Laboratories. 10–12 week old BALB/c mice were
infected with 1x107 PruQ-parental strain or PruQ-Δap2IV-4 intraperitoneally in sterile PBS.
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Uninfected, age-matched mice were used as naïve uninfected controls. Mice were monitored
daily and euthanized at day one and day six-post infection for study.
To examine acute virulence and tissue cyst formation, 5–6 week old female BALB/c mice
were injected intraperitoneally with 105, 106, or 107 PruQ-parent or PruQΔap2IV-4 parasites
(4 mice per group, 107 dose only shown in Fig 4). Plaque assays were performed for each sam-
ple and ensured equal viability between strains. Mice were examined daily and time to death
was recorded. Serology performed on cardiac bleeds of infected mice confirmed presence of
Toxoplasma. To assess cyst burden, BALB/c mice were infected with 1x106 parasites as
described above and allowed to progress to chronic infection for 30 days (4 mice per group).
Brains were then homogenized; homogenates were fixed, quenched, and permeabilized. Sam-
ples were blocked in 3% BSA/1xPBS/0.2% Triton X-100. To visualize cyst walls, rhodamine-
conjugated Dolichos biflorus lectin (Vector Labs) was applied at 1:250 dilution overnight at
4˚C. Cyst quantification was performed as previously described [62].
Cell collection and flow cytometry
Following euthanasia, peritoneal exudate cells (PECs) were collected from the peritoneal cavity
in sterile PBS. Cells were counted using an automated cell counter, and total cell numbers
were determined using the volume recovered from the peritoneum. Aliquots were used for
cytospins, and stained using HEMA3 stains. For flow cytometry, cells were incubated with
1:10 FC Block (BD, 553142) for 5 minutes on ice, and subsequently incubated with fluoro-
phore-conjugated antibodies to CD45, CD11b, CD11c, Ly6C, Ly6G. Cells were washed, resus-
pended in FACS buffer and samples acquired using a BD FACS Canto II flow cytometer.
Analysis was conducted using Flowjo software.
Parasite burden
Peripheral tissues were placed in tissue lysis buffer for DNA isolation. DNA was isolated using
a genomic DNA purification kit (Roche, 11796828001). To quantify parasite burden, quantita-
tive PCR (Bioline) was conducted on isolated DNA by amplification of the Toxoplasma B1
gene (F: 5’ TCCCCTCTGCTGGCGAAAAGT 3’ R: 5’ AGCGTTCGTGGTCAACTATCG 3’).
Parasite burden was quantified using a standard curve as previously described [63].
Ethics statement
All animal research was conducted in accordance with the animal welfare act, and all protocols
were approved by the Institutional Animal Care and Use Committees at the University of Cali-
fornia, Riverside (approved protocol #A-20140007) or the Indiana University School of Medi-
cine (approved protocol #10852).
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S1 Fig. AP2IV-4 and AP2VI-1 expression during daughter budding. (A.) The AP2IV-4 sin-
gle exon and AP2 domain gene is predicted to encode a ~250kDa protein (http://toxodb.org/
toxo/app/record/gene/TGME49_318470), which was confirmed by Western analysis (α-HA)
of AP2IV-4HA parasites (plus 3xHA, actual protein size is ~254kDa). Molecular mass standards
indicated on the left. (B.) IFA analysis of AP2IV-4HA and AP2VI-1HA transgenic parasites
grown in HFF monolayers utilized co-stains α-HA (green, AP2IV-4HA or AP2VI-1HA expres-
sion) and α-IMC1 (black and white panels). To improve visualization of internal bud struc-
tures, IMC1 images were decolorized and then inverted. AP2IV-4HA and AP2VI-1HA are
exclusively localized to the nucleus and the relative cell cycle expression profile predicted by
the cyclical mRNA patterns (Fig 1A, green and red curves) was confirmed for each factor.
Black scale bar = 5 μm.
(TIF)
S2 Fig. Developmental expression of AP2IV-4. (A.) Representative microscope field showing
two vacuoles of PruQ-AP2IV-4HA parasites; one vacuole is synchronously expressing AP2IV-
4HA, while the other is negative for this factor due to the cell cycle regulation of AP2IV-4
expression. IFA analysis utilized co-stains α-HA (red, AP2IV-4HA) and α-IMC1 (green). (B.)
Quantification of AP2IV-4HA expression in tachyzoites and alkaline-shifted bradyzoites at the
times indicated. 100 randomly selected vacuoles stained with α-HA (red, AP2IV-4HA) and
DBA were counted in triplicate. Tissue cysts (DBA+) that were also positive for AP2IV-4HA
were sorted into five bins based on the fraction of AP2IV-4HA positive parasites. IFA images
showing representative patterns of AP2IV-4HA expression in the tissue cysts from each of the
five bins (cell cycle marker IMC1 and AP2IV-4HA co-stains) is shown below the graph. (C.)
Representative image of a differentiating vacuole (72 h post-alkaline shift) co-stained with α-
centrin (centrosome) and α-HA (AP2IV-4HA). Note the distinct morphology of the two
AP2IV-4HA parasites that possessed a duplicated centrosome adjacent to the nucleus, which
are likely mitotic. In contrast to the uniform centrin staining in the AP2IV-4HA-positive para-
sites, centrin staining in the AP2IV-4HA-negative parasites varied in intensity and composition
with many parasites containing a faint, single dot of centrin.
(TIF)
S3 Fig. Genetic knockout strategy for AP2IV-4. (A.) Verification of AP2IV-4 knockout by
RT-PCR in the RHCre-Δap2IV-4 transgenic clones. AP2IV-4 mRNA is detected in lane P (par-
ent strain, RHCre-AP2IV-4floxed), but absent from both AP2IV-4 knockout clones evaluated
(RHCre-Δap2IV-4 clones 27, and 30). For a diagram of the RHCre knockout strategy see Fig
3A. Complementation for the loss of AP2IV-4 in RHCre-Δap2IV-4 parasites was accomplished
using cosmid PSBM794, which reintroduces a full copy of the AP2IV-4 gene and restores
AP2IV-4 mRNA expression (C lanes). (B.) Diagram of the AP2IV-4 knockout strategy in Type
II PruQ-parent (AP2IV-4floxed), which is similar to the knockout of AP2IV-4 in the RHCre
strain (see Fig 3A). Here transient transfection of pMIN-CRE-eGFP plasmid into the PruQ-A-
P2IV-4floxed strain was required to introduce active Cre recombinase. (C.) PruQ-parent (lane
P) expresses the expected AP2IV-4 transcript, whereas PruQ-Δap2IV-4 clones 10 and 34 (lanes
Δ10 and Δ34) lack the AP2IV-4 mRNA. AP2IV-4 cDNA primers amplify a 1367bp fragment
of the single exon gene (7221bp full length). For loading and template quality control, GAPDH
primers were designed around a 432bp intron, allowing detection of both mRNA (202bp,
intron spliced out) and contaminating genomic DNA (634 bp). The absence of a detectable
634bp amplicon in all samples indicates the RNA templates were free of genomic DNA con-
tamination. See S3 Dataset for all primer designs.
(TIF)
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S4 Fig. Deletion of the AP2IV-4 gene in the RHCre strain leads to de-repression of brady-
zoite surface and cyst wall mRNAs and proteins in the tachyzoite stage. (A.) RHCre-parent
(AP2IV-4floxed, open bar), -Δap2IV-4 knockout (black bar), and -Δap2IV-4::AP2IV-4 comple-
mented (grey bar) parasites were grown in HFF cells for 24 h under standard tachyzoite culture
conditions (pH 7.0) and then IFA analysis performed using α-IMC1 (green stain, tachyzoite
replication marker) and antibodies to cyst wall protein, CST1 (red stain). Scale bar = 5 μm.
CST1 positive vacuoles in each strain were quantified in triplicate by counting 100 vacuoles in
randomly selected microscopic fields (, p<0.01). Increased expression of CST1 protein in
two independent RHCre-Δap2IV-4 clones (Δ clones, see also S3A Fig) compared to the
RHCre-parental (P = AP2IV-4floxed) strain revealed by Western analysis. Nucleolar TgNF3
(43kDa) protein was included as a loading control. Protein mass markers 230kDa and 50 kDa
on left. Immunofluorescence images included on right are representative of CST1 positive vac-
uoles showing cyst wall localization in RHCre-Δap2IV-4 parasites. (B.) Representative IFA
images of RHCre-Δap2IV-4 tachyzoites expressing bradyzoite-specific proteins BPK1 and
MCP4 with normal localization at the periphery of the vacuole consistent with DBA+ cyst wall
structures, likewise expression of bradyzoite-specific SRS9 in the RHCre-Δap2IV-4 tachyzoites
was properly localized to the parasite surface. Note the uniform intravacuolar expression of
SRS9 in RHCre-Δap2IV-4. Scale bar = 5 μm. (C.) Numbers of BPK1, MPC4, DBA, and SRS9
positive vacuoles in RHCre-parent, RHCre-Δap2IV-4 and RHCre-Δap2IV-4:AP2IV-4 tachy-
zoites. Statistical significance indicated (, p<0.01; , p<0.001). Positive staining vacuoles
for each strain were quantified in triplicate by counting 100 vacuoles in randomly selected
microscopic fields.
(TIF)
S5 Fig. AP2IV-4 knockout parasites retain dominant tachyzoite phenotypes. (A.) The cell
cycle distribution of SRS9+ parasites in PruQ-Δap2IV-4 versus the PruQ-parent strains was
determined by IFA analysis with αSRS9 and αCentrin (centrosome marker) antibodies. Repre-
sentative PruQ-Δap2IV-4 co-stained images demonstrate the association of SRS9 expression
with parasites containing duplicated centrosomes (S/M/C phases) that was quantified and
graphed for PruQ-Δap2IV-4 and the PruQ-parent strains. All parasite counts were determined
in triplicate from 100 vacuoles selected at random. The association of SRS9+ expression in S
phase and mitotic PruQ-Δap2IV-4 parasites (duplicated centrosome) versus G1 phase (single
centrosome) parasites was statistically significant (p<0.001). Scale bar = 5 μm. (B.) The tachy-
zoite nature of SRS9+ PruQ-Δap2IV-4 parasites was confirmed by IFA analysis with αSRS9
and αSAG1 antibodies. The expression of SRS9 in PruQ-Δap2IV-4 parasites was nearly ~50%
(as shown in A.), and thus, about half the population was SAG1+/SRS9- (#1 vacuole of four
parasites circled). Nearly all PruQ-Δap2IV-4 parasites expressing SRS9+ were also positive for
SAG1+ surface expression (representative vacuole #3 circled). The fraction of SAG1+ positive
vacuoles in PruQ-parent and PruQ-Δap2IV-4 (SRS9- and SRS9+) infected HFF cell cultures
were quantified (see graph). In rare examples, PruQ-Δap2IV-4 parasites that were SRS9+ also
showed diminished SAG1 expression (#2 vacuole circled). Scale bar = 5 μm (C.) Whole-cell
mRNA analysis of Type II PruQ-Δap2IV-4 parasites. The analysis of total mRNA expression of
PruQ-Δap2IV-4 versus PruQ-parent parasites grown under tachyzoite conditions shows nearly
complete identity (r = 0.984) with the exception of the few mRNAs altered by the loss of
AP2IV-4 (Fig 3A and S1 Dataset). Note mRNAs misexpressed by the loss of AP2IV-4 have
higher levels in the PruQ-Δap2IV-4 parasites, while few tachyzoite mRNAs are downregulated.
A reference plot for native Type II strain (M4 isolate) differences (r = 0.786) in developmental
mRNA expression of tachyzoites versus bradyzoites is shown. Type II M4 strain data was
obtained from the GEO repository (accession #GSE32427). Type II PruQ-parent and PruQ-
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Δap2IV-4 mRNA data is also deposited in GEO (accession #GSE93531). The mRNA levels for
SRS9, MCP4, and BPK1 are indicated by the indicated colored circles in each plot. AP2IV-4
mRNA levels (red circle) are only indicated in the PruQ plot. All mRNA expression data was
log2 transformed.
(TIF)
S6 Fig. PruΔap2IV-4 parasites infect equivalently to the PruQ-parent and complemented
strains at day one, but are mostly absent by day 6 post-infection. (A.) Peritoneal exudate
cells were collected at one day post-infection with 107 tachyzoites intraperitoneally. Cells from
the peritoneal wash were spun onto cytoslides and stained hematologically. Representative
images at both 25X and 63X are provided. Representative parasite vacuoles are marked by a
(). (B.) Cytospins of peritoneal washes from animals six days post-infection were harvested
and stained as above. Percentages of infected monocytes and polymorphonuclear neutrophils
were determined by microscopy.
(TIF)
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